These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

854 related items for PubMed ID: 20026803

  • 1. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
    Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF.
    J Clin Oncol; 2010 Feb 01; 28(4):556-61. PubMed ID: 20026803
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Sekeres MA.
    Best Pract Res Clin Haematol; 2013 Sep 01; 26(3):275-8. PubMed ID: 24309530
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Cashen AF, Shah AK, Todt L, Fisher N, DiPersio J.
    Cancer Chemother Pharmacol; 2008 Apr 01; 61(5):759-66. PubMed ID: 17564707
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients.
    Lübbert M, Bertz H, Rüter B, Marks R, Claus R, Wäsch R, Finke J.
    Bone Marrow Transplant; 2009 Nov 01; 44(9):585-8. PubMed ID: 19363531
    [Abstract] [Full Text] [Related]

  • 11. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
    Duong VH, Bhatnagar B, Zandberg DP, Vannorsdall EJ, Tidwell ML, Chen Q, Baer MR.
    Leuk Lymphoma; 2015 Jun 01; 56(6):1718-22. PubMed ID: 25263320
    [Abstract] [Full Text] [Related]

  • 12. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
    Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H.
    Lancet Oncol; 2015 Sep 01; 16(9):1099-1110. PubMed ID: 26296954
    [Abstract] [Full Text] [Related]

  • 13. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
    Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ.
    Lancet Oncol; 2017 Oct 01; 18(10):1317-1326. PubMed ID: 28844816
    [Abstract] [Full Text] [Related]

  • 14. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
    Pan F, Peng S, Fleurence R, Linnehan JE, Knopf K, Kim E.
    Clin Ther; 2010 Dec 01; 32(14):2444-56. PubMed ID: 21353113
    [Abstract] [Full Text] [Related]

  • 15. Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia.
    Park H, Chung H, Lee J, Jang J, Kim Y, Kim SJ, Kim JS, Min YH, Cheong JW.
    Yonsei Med J; 2017 Jan 01; 58(1):35-42. PubMed ID: 27873493
    [Abstract] [Full Text] [Related]

  • 16. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
    van der Helm LH, Alhan C, Wijermans PW, van Marwijk Kooy M, Schaafsma R, Biemond BJ, Beeker A, Hoogendoorn M, van Rees BP, de Weerdt O, Wegman J, Libourel WJ, Luykx-de Bakker SA, Minnema MC, Brouwer RE, Croon-de Boer F, Eefting M, Jie KS, van de Loosdrecht AA, Koedam J, Veeger NJ, Vellenga E, Huls G.
    Br J Haematol; 2011 Dec 01; 155(5):599-606. PubMed ID: 21981697
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
    Filì C, Candoni A, Zannier ME, Olivieri J, Imbergamo S, Caizzi M, Nadali G, Di Bona E, Ermacora A, Gottardi M, Facchinelli D, Ciancia R, Lazzarotto D, Dubbini MV, Festini G, Gherlinzoni F, Michieli MG, Semenzato G, Fanin R.
    Leuk Res; 2019 Jan 01; 76():33-38. PubMed ID: 30529681
    [Abstract] [Full Text] [Related]

  • 19. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
    Kirschbaum M, Gojo I, Goldberg SL, Bredeson C, Kujawski LA, Yang A, Marks P, Frankel P, Sun X, Tosolini A, Eid JE, Lubiniecki GM, Issa JP.
    Br J Haematol; 2014 Oct 01; 167(2):185-93. PubMed ID: 25040094
    [Abstract] [Full Text] [Related]

  • 20. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
    Cabrero M, Jabbour E, Ravandi F, Bohannan Z, Pierce S, Kantarjian HM, Garcia-Manero G.
    Leuk Res; 2015 May 01; 39(5):520-4. PubMed ID: 25828745
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.